Aoxiang Pharmaceutical (603229.SH) announced its 2023 annual results. Net profit of 254 million yuan increased 7.87% year over year
Aoxiang Pharmaceutical (603229.SH) released its 2023 annual performance report. During the reporting period, the company achieved an operating income of 8...
Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) CEO Zhiguo Zheng Is the Most Upbeat Insider, and Their Holdings Increased by 6.9% Last Week
Key Insights Zhejiang Ausun Pharmaceutical's significant insider ownership suggests inherent interests in company's expansion The largest shareholder of the company is Zhiguo Zheng with a 51% stake
Zhejiang Ausun Pharmaceutical (SHSE:603229) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Zhejiang Ausun Pharmaceutical's (SHSE:603229) Five-year Earnings Growth Trails the 23% YoY Shareholder Returns
While Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 25% in the last
Aoxiang Pharmaceutical (603229.SH): Currently, the company's business does not involve blockchain technology
Gelonghui, Feb. 1: Aoxiang Pharmaceutical (603229.SH) said on the investor interactive platform that its current business does not involve blockchain technology.
The Market Doesn't Like What It Sees From Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Earnings Yet As Shares Tumble 26%
To the annoyance of some shareholders, Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) shares are down a considerable 26% in the last month, which continues a horrid run for the company. The
Is Weakness In Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
It is hard to get excited after looking at Zhejiang Ausun Pharmaceutical's (SHSE:603229) recent performance, when its stock has declined 12% over the past month. But if you pay close attention, you
We Think Zhejiang Ausun Pharmaceutical (SHSE:603229) Can Stay On Top Of Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
The Recent 13% Gain Must Have Brightened CEO Zhiguo Zheng's Week, Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Most Bullish Insider
Key Insights Zhejiang Ausun Pharmaceutical's significant insider ownership suggests inherent interests in company's expansion Zhiguo Zheng owns 71% of the company 12% of Zhejiang Ausun Pharmaceut
Aoxiang Pharmaceutical (603229.SH) released results for the first three quarters, with net profit of 225 million yuan, an increase of 27.25%
Aoxiang Pharmaceutical (603229.SH) released its report for the third quarter of 2023, achieving operating income of 6.7 in the first three quarters...
Zhejiang Ausun Pharmaceutical (SHSE:603229) Jumps 7.7% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock performs well, when investors win, they can win big. Don't believe it? Then look at
Aoxiang Pharmaceutical (603229.SH) released first-half results, net profit of 160 million yuan, an increase of 30.22% over the previous year
Aoxiang Pharmaceutical (603229.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
Aoxiang Pharmaceutical (603229.SH): 3.456 million restricted shares lifted on August 3
On July 28, GLONGHUI | Aoxiang Pharmaceutical (603229.SH) announced that the total number of shares listed and circulated by the company is 3.456 million shares. The stock listing and circulation date is August 3, 2023.
Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) CEO Zhiguo Zheng's Holdings Dropped 4.0% in Value as a Result of the Recent Pullback
Key Insights Significant insider control over Zhejiang Ausun Pharmaceutical implies vested interests in company growth The largest shareholder of the company is Zhiguo Zheng with a 51% stake Inst
Aoxiang Pharmaceutical (603229.SH) 2022 equity distribution: 0.4 to 0.112 yuan per share equity registration on July 11
According to the Zhitong Finance App, Aoxiang Pharmaceutical (603229.SH) announced that the company's 2022 annual equity distribution plan is: based on the company's total share capital before the implementation of the plan, a cash dividend of 0.112 yuan (tax included) per share, using the capital provident fund to transfer 0.4 shares per share to all shareholders. The share registration date is July 11, 2023, and the exemption (interest) date is July 12, 2023.
The Total Return for Zhejiang Ausun Pharmaceutical (SHSE:603229) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years
It hasn't been the best quarter for Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) shareholders, since the share price has fallen 12% in that time. But that scarcely detracts from the really
Ausun Pharma's Unit Passes Regulatory Inspection
01:35 AM EDT, 05/08/2023 (MT Newswires) -- Zhejiang Qizheng Pharmaceutical, a unit of Zhejiang Ausun Pharmaceutical (SHA:603229), passed the good manufacturing practice or GMP compliance inspection of
Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Zhejiang Ausun Pharmaceutical (SHSE:603229) has had a rough month with its share price down 10%. However, stock prices are usually driven by a company's financial performance over the long term, whi
Should You Be Adding Zhejiang Ausun Pharmaceutical (SHSE:603229) To Your Watchlist Today?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But the
Zhejiang Ausun Pharmaceutical's (SHSE:603229) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
While Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 10% in the last
No Data